DeNovX is ...
an innovative pharmaceutical technology company that provides platform products and services that accelerate pharmaceutical development while creating new intellectual property (IP) for commercially relevant drugs.
Over 90% of active pharmaceutical ingredients (APIs) are crystalline solids, and our platform technologies reduce the risks associated with controlling the size, shape, and structure of these high value materials while creating new IP to enhance competitive advantage and to extend product life cycles.
Think Forward - to rational crystal screening and solid form controls.
Control of the size, shape, and structure of crystalline active pharmaceuticals ingredients remains a challenge in R&D and production.
Screening with crystallization platforms based on self assembled monolayers (SAMs) is fast and mass efficient.
Work with us to explore continuous crystallization processes that replace costly batch methods and give better control of crystal size distribution.